{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:26:53Z","timestamp":1793370413824,"version":"4.5.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>TSH-receptor antibodies (TRAb) directed against the TSH receptor (TSH-R) induce hyperthyroidism in patients with Graves\u2032 disease (GD). TRAb detected by previous radioimmunoassay only reflects the presence of autoantibodies, but not the function of such antibodies. Thyroid stimulating immunoglobulins (TSI) is a relatively new method for assessing TSH-receptor antibodies function. The aim of this study was to investigate the role of TSI in the diagnosis and management of GD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with newly diagnosed GD (n=140, age 38.00 \u00b1 11.99 years, 106 women) received pharmacological therapy (methimazole) up to 18 months in the outpatient or inpatient department of the Second People\u2019s Hospital of Foshan City from January 2013 to December 2018. GD was identified by clinical signs and symptoms and relevant laboratory tests. Blood samples for TSI and TRAb and other thyroidal biomarkers were obtained at baseline and at three times during the follow-up. All patients with GD were followed up for at least 5 years to see if the patient was cured or had relapsed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>TSI and TRAb in GD patients were significantly higher than those in the normal control group (<jats:italic>P<\/jats:italic>&amp;lt;0.001), and there was a strong correlation between TSI and TRAb in GD patients (<jats:italic>P<\/jats:italic>&amp;lt;0.001). After treatment, TSI and TRAb significantly decreased (<jats:italic>P<\/jats:italic>&amp;lt;0.05), TSI and TRAb in patients with disease course more than 2 years were significantly higher than those in patients with disease course less than 2 years (<jats:italic>P<\/jats:italic>&amp;lt;0.05), There was no statistically significant difference in TSI and TRAb at initial diagnosis between patients with a disease duration of more than 2 years and less than 5 years and those with a disease duration of more than 5 years (<jats:italic>P<\/jats:italic>&amp;gt;0.05); if the patients were still positive for TSI or TRAb antibodies at 5 years of follow-up after treatment with anti-hyperthyroidism medication, the patients were at a higher risk of relapse (<jats:italic>P<\/jats:italic>&amp;lt;0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The higher TSI at the initial diagnosis of GD, the longer duration of treatment with anti-hyperthyroid drugs and the higher risk of relapse. Compared with TRAb, serum TSI level is also important in the clinical diagnosis and prognosis of GD, but which one is superior to the other needs further study.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1487490","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T04:18:41Z","timestamp":1732767521000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparison between thyroid stimulating immunoglobulin and TSH-receptor antibodies in the diagnosis and management of Graves\u2019 disease"],"prefix":"10.3389","volume":"15","author":[{"given":"Peiwei","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunliang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingwen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510030","article-title":"Graves' disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1159\/000490384","article-title":"2018 European thyroid association guideline for the management of graves' hyperthyroidism","volume":"7","author":"Kahaly","year":"2018","journal-title":"Eur Thyroid J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1559633","article-title":"Graves' disease mechanisms: the role of stimulating, blocking, and cleavage region TSH receptor antibodies","volume":"47","author":"Morshed","year":"2015","journal-title":"Horm Metab Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e22468","article-title":"Comparison of two different TSH-receptor antibody assays: A clinical practice study","volume":"9","author":"van Balkum","year":"2023","journal-title":"Heliyon"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/182176","article-title":"Changes of TSH-stimulation blocking antibody (TSBAb) and thyroid stimulating antibody (TSAb) over 10 years in 34 TSBAb-positive patients with hypothyroidism and in 98 TSAb-positive graves\u2019 patients with hyperthyroidism: reevaluation of TSBAb and TSAb in TSH-receptor-antibody (TRAb)-positive patients","volume":"2012","author":"Takasu","year":"2012","journal-title":"J Thyroid Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz292","article-title":"Prospective trial of functional thyrotropin receptor antibodies in Graves disease","volume":"105","author":"Kahaly","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01380-9","article-title":"Thyrotropin receptor antibodies and Graves' orbitopathy","volume":"44","author":"Diana","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.13406\/j.cnki.cyxb.003132","article-title":"Correlation between thyrotropin receptor antibody and thyroid-stimulating immunoglobulin and methimazole responsiveness in patients with Graves' disease","volume":"47","author":"Chen","year":"2022","journal-title":"J Chongqing Med Univ"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1055\/a-2021-0596","article-title":"Comparison between thyroid stimulating immunoglobulin and TSH-receptor antibodies in management of Graves \u2018orbitopathy","volume":"131","author":"Khamisi","year":"2023","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.clinbiochem.2021.07.014","article-title":"Clinical efficacy of thyroid-stimulating immunoglobulin detection for diagnosing Graves' disease and predictors of responsiveness to methimazole","volume":"97","author":"Liu","year":"2021","journal-title":"Clin Biochem"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02386-2","article-title":"Clinical diagnostic performance of a fully automated TSI immunoassay vs. that of an automated anti-TSHR immunoassay for Graves' disease: a Chinese multicenter study","volume":"71","author":"Cheng","year":"2021","journal-title":"Endocrine"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14130","article-title":"Diagnostic testing for Graves' or non-Graves' hyperthyroidism: a comparison of two thyrotropin receptor antibody immunoassays with thyroid scintigraphy and ultrasonography","volume":"92","author":"Scappaticcio","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/20420188211044943","article-title":"The prognostic value of thyroid-stimulating immunoglobulin in the management of Graves' disease","volume":"12","author":"Zhou","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s12020-014-0325-8","article-title":"High cut-off value of a chimeric TSH receptor (Mc4)-based bioassay may improve prediction of relapse in Graves' disease for 12 months","volume":"48","author":"Hwang","year":"2015","journal-title":"Endocrine"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.22190","article-title":"Thyroid-stimulatory antibody as a predictive factor for Graves' disease relapse","volume":"14","author":"Da Silva Santos","year":"2022","journal-title":"Cureus"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2016.31.2.300","article-title":"Usefulness of measuring thyroid stimulating antibody at the time of antithyroid drug withdrawal for predicting relapse of Graves\u2019 disease","volume":"31","author":"Kwon","year":"2016","journal-title":"Endocrinol Metab (Seoul)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvac023","article-title":"The prediction model using thyroid-stimulating immunoglobulin bioassay for relapse of Graves' disease","volume":"6","author":"Baek","year":"2022","journal-title":"J Endocr Soc"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1487490\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T04:18:43Z","timestamp":1732767523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1487490\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":18,"alternative-id":["10.3389\/fendo.2024.1487490"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1487490","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"article-number":"1487490"}}